IP Library Granted Patent US 7,915,297
Granted Patent B2
US 7,915,297 · App. 12/159,718 · Granted Mar 29, 2011

Isoxazole derivatives and use thereof

Assignee: SK Holdings Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,915,297
App. No.
12/159,718
Granted
Mar 29, 2011
Kind
B2
Abstract

Disclosed herein are isoxazole derivatives and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

Claims (78)

1. An isoxazole derivative of the following Chemical Formula 1, or a pharmaceutically acceptable salt thereof:

wherein,

R 1 is an aryl group selected from the group consisting of thienyl, furanyl and phenyl that may be unsubstituted or substituted with one or more substituents selected from the group consisting of acyl, amino, carboalkoxy, carboxy, carboxyamino, —O-carbamoyl, cyano, halo, hydroxy, nitro, thio, alkyl, cycloalkyl, aryl, alkoxy, aryloxy, sulfoxy and guanido;

R 2 is hydrogen; and

X is a substituent of the following Chemical Formula 2;

wherein R 3 is hydrogen,

R4 is an alkyl group substituted with an aryl group selected from the group consisting of phenyl, imidazolyl, triazolyl, and pyridyl, wherein the alkyl group is further unsubstituted and said phenyl, imidazolyl, triazolyl, and pyridyl may be unsubstituted or substituted with one or more substituents selected from the group consisting of amino, carboalkoxy, carboxy, halo, hydroxy, nitro, alkyl, and alkoxy

wherein, when R4 is an alkyl group substituted with an aryl group and R1 is substituted or unsubstituted phenyl, said aryl group is imidazolyl or triazolyl.

2. An isoxazole derivative or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein the isoxazole derivative is selected from a group consisting of the following compounds:

(1) 5-furan-2-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(10): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-pyridin-2-yl-ethyl)-amide,

(11): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-pyridin-3-yl-ethyl)-amide,

(12): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-pyridin-4-yl-ethyl)-amide,

(33): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide,

(35): 5-furan-2-yl-isoxazole-3-carboxylic acid [2-(2-methyl-imidazol-1-yl)-ethyl]-amide,

(36): 5-furan-2-yl-isoxazole-3-carboxylic acid [2-(5-methyl-imidazol-1-yl)-ethyl]-amide,

(37): 5-furan-2-yl-isoxazole-3-carboxylic acid [2-(4-methyl-imidazol-1-yl)-ethyl]-amide,

(38): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-[1,2,4]triazol-1-yl-ethyl)-amide,

(40): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-[1,2,3]triazol-2-yl-ethyl)-amide,

(41): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-[1,2,3]triazol-1-yl-ethyl)-amide,

(44): 5-furan-2-yl-isoxazole-3-carboxylic acid [3-(2-methyl-imidazol-1-yl)-propyl]-amide,

(49): 5-furan-2-yl-isoxazole-3-carboxylic acid (3-[1,2,3]triazol-1-yl-propyl)-amide,

(50): 5-furan-2-yl-isoxazole-3-carboxylic acid (3-[1,2,3]triazol-2-yl-propyl)-amide,

(51): 5-furan-2-yl-isoxazole-3-carboxylic acid (3-[1,2,4]triazol-1-yl-propyl)-amide,

(56): 5-furan-2-yl-isoxazole-3-carboxylic acid [3-(4-methyl-imidazol-1-yl)-propyl]-amide,

(68): 5-phenyl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(69): 5-phenyl-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide,

(78): 5-o-tolyl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(79): 5-m-tolyl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(80): 5-p-tolyl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(81): 5-(2-fluoro-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(82): 5-(3-fluoro-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(83): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(84): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (3-[1,2,4]triazol-1-yl-propyl)-amide,

(85): 5-(2-fluoro-phenyl)-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide,

(86): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide,

(88): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (2-[1,2,4]triazol-1-yl-ethyl)-amide,

(89): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (2-[1,2,3]triazol-2-yl-ethyl)-amide,

(90): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (2-[1,2,3]triazol-1-yl-ethyl)-amide,

(96): 5-(4-chloro-phenyl)-isoxazole-3-carboxylic acid (3-[1,2,4]triazol-1-yl-propyl)-amide,

(97): 5-(4-chloro-phenyl)-isoxazole-3-carboxylic acid (2-[1,2,4]triazol-1-yl-ethyl)-amide,

(98): 5-(4-chloro-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(99): 5-(2-methoxy-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(100): 5-(3-methoxy-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(101): 5-(4-methoxy-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(113): 5-(3-nitro-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(114): 5-(4-nitro-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(119): 5-(3-amino-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(120): 5-(4-amino-phenyl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(131): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(132): 5-thiophen-2-yl-isoxazole-3-carboxylic acid-(3-[1,2,4]-triazol-1-yl-propyl)-amide,

(133): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide,

(135): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-[1,2,4]triazol-1-yl-ethyl)-amide,

(136): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-[1,2,3]triazol-2-yl-ethyl)-amide,

(137): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-[1,2,3]triazol-1-yl-ethyl)-amide,

(139): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-pyridin-3-yl-ethyl)-amide,

(140): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-pyridin-4-yl-ethyl)-amide,

(143): 5-(5-bromo-thiophen-2-yl)-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(152): 5-furan-3-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(153): 5-furan-3-yl-isoxazole-3-carboxylic acid (3-[1,2,4]-triazol-1-yl-propyl)-amide,

(154): 5-furan-3-yl-isoxazole-3-carboxylic acid (2-[1,2,4]-triazol-1-yl-ethyl)-amide,

(155): 5-thiophen-3-yl-isoxazole-3-carboxylic acid (3-[1,2,4]-triazol-1-yl-propyl)-amide,

(156): 5-thiophen-3-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(157): 5-thiophen-3-yl-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide, and

(158): 5-thiophen-3-yl-isoxazole-3-carboxylic acid (2-[1,2,4]-triazol-1-yl-ethyl)-amide.

3. A pharmaceutical composition comprising an isoxazole derivative in accordance with claim 2 selected from the group consisting of:

(1) 5-furan-2-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(10): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-pyridin-2-yl-ethyl)-amide,

(12): 5-furan-2-yl-isoxazole-3-carboxylic acid (2-pyridin-4-yl-ethyl)-amide,

(49): 5-furan-2-yl-isoxazole-3-carboxylic acid (3-[1,2,3]triazol-1-yl-propyl)-amide,

(68): 5-phenyl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(84): 5-(4-fluoro-phenyl)-isoxazole-3-carboxylic acid (3-[1,2,4]triazol-1-yl-propyl)-amide,

(131): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide,

(132): 5-thiophen-2-yl-isoxazole-3-carboxylic acid-(3-[1,2,4]-triazol-1-yl-propyl)-amide,

(133): 5-thiophen-2-yl-isoxazole-3-carboxylic acid (2-imidazol-1-yl-ethyl)-amide,

(156): 5-thiophen-3-yl-isoxazole-3-carboxylic acid (3-imidazol-1-yl-propyl)-amide, and

(158): 5-thiophen-3-yl-isoxazole-3-carboxylic acid (2-[1,2,4]-triazol-1-yl-ethyl)-amide

in a therapeutically effective amount to treat postmenopausal osteoporosis and osteoarthropathy and a pharmaceutically acceptable carrier suitable for formulating the composition into oral, parenteral, or transdermal preparations.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2012
From: SK HOLDINGS CO., LTD.
To: SK BIOPHARMACEUTICALS CO., LTD.
Reel/Frame 027558/0316 →
THE ASSIGNMENT WAS SUBMITTED UPSIDE DOWN AND WE ARE RESUBMITTING RIGHT SIDE UP. DOCUMENT ID NO.: 500651492 Recorded Sep 25, 2008
From: CHO, JEONG-WOO; CHOI, SANG RAK; HWANG, SUN GWAN; CHO, KYUNG CHUL; BAE, SUNG JIN; KOO, TAE SUNG
To: SK HOLDINGS CO., LTD.
Reel/Frame 021584/0770 →
Priority Claims (2)
KR 10-2005-0135247 · Dec 30, 2005 · national
KR 10-2006-0135390 · Dec 27, 2006 · national
Continuity (1)
Related Publication 20090131336A1 · May 21, 2009